Therma Bright Inc. (TSX-V: THRM, OTC: THRBF, Forum) announced on Thursday that it had received institutional review board approval and subsequently submitted to Health Canada seeking approval to conduct a clinical performance study of its AcuVid COVID-19 Rapid Saliva-based Antigen Test.
Therma Bright’s Chief Executive Officer, Rob Fia called this another significant milestone in moving the AcuVi test closer to market.
“We look forward to beginning the trial in Ontario, Canada as we explore other potential sites in the US, South America and Europe that will generate additional data to support our applications in those jurisdictions.”
For the full rundown on this story, click
here.
The medical device technology Company also
made news this week when it entered into business agreement with Ridge Global, the consultancy founded by Governor Tom Ridge, the first US Secretary of Homeland Security. The agreement focuses on supporting the Company's reach across the United States and Global marketplace business community along with extending policy advisory services in the US.
CEO Fia called this a solid asset to THRM’s advisory team.
“Governor Ridge will serve as a Senior Advisor and support his team in corporate strategy and business development on behalf of Therma Bright.”
FULL DISCLOSURE: Therma Bright Inc. is a client of Stockhouse Publishing.